Matinas BioPharma Holdings, Inc.
MTNBNYSEAMERICANHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $1.03M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $0.48$13.60
- Volume (live)
- -
- Avg. volume (3M)
- 99.52K
Matinas BioPharma Holdings (MTNB) Stock Price & Financial Analysis
Matinas BioPharma Holdings Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.36 - $2.50 |
|---|---|
| 52-Week High | $13.60 |
| 52-Week Low | $0.48 |
| Open | $2.48 |
| Volume (last close) | 24.51K |
| Average Volume (3M) | 99.52K |
| 50-Day MA | $2.95 |
|---|---|
| 200-Day MA | $1.92 |
| 1-Year Change | +39.08% |
| Market Cap | 1.03M |
|---|---|
| Shares Outstanding | 427.08K |
| Price to Book (P/B) | 0.57 |
| EV/EBITDA | -0.04 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Matinas BioPharma Holdings at a Glance
As of the Oct 16, 2026 close, Matinas BioPharma Holdings (MTNB) has a market capitalization of $1.03M.
As of its latest reported balance sheet, it holds $761.00K in cash and securities against $6.00K of debt, a net cash position of $755.00K.
Matinas BioPharma Holdings does not currently pay a dividend.
The share price is up 39.1% over the past year. At $2.37 (the Oct 16, 2026 close) it sits near the bottom of its 52-week range of $0.48 to $13.60, above its 200-day moving average of $1.92.
Frequently Asked Questions About Matinas BioPharma Holdings
What is the current stock price for MTNB?
As of the Oct 16, 2026 close, MTNB stock trades at $2.37. The 52-week range is $0.48–$13.60, with a day range of $2.36–$2.50.
What is the P/E ratio for MTNB?
The P/E ratio (Price-to-Earnings) for MTNB is shown in the Key Statistics section. This valuation metric helps compare Matinas BioPharma Holdings, Inc. to industry peers.
Does MTNB pay dividends?
Matinas BioPharma Holdings does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for MTNB?
Analyst ratings and recommendations for MTNB are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of MTNB?
As of the Oct 16, 2026 close, Matinas BioPharma Holdings's market capitalization is $1.0M, classifying it as a micro-cap company. Matinas BioPharma Holdings operates in the Healthcare sector within the Biotechnology industry.